Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary

Praxis Precision Medicines

06/08/2026 15:07

Praxis Precision Medicines, Inc. PRAX.OQ reported a quarterly adjusted loss of $2.87​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.31.  The mean expectation of nineteen analysts for the quarter was for a loss of $3.66 per share. Wall Street expected results to range from $-5.09 to $-3.04 per share.
Reported revenue was zero​; analysts expected zero. 
Praxis Precision Medicines, Inc.'s reported EPS for the quarter was a loss of $2.87​.
The company reported a quarterly loss of $83.72 million.
Praxis Precision Medicines, Inc. shares had fallen by 4.6% this quarter and gained 8.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 2.3% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Praxis Precision Medicines, Inc. is $550.00, about 42% above its last closing price of $319.23
This summary was machine generated from LSEG data August 6 at 02:07 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-3.66
-2.87
Beat
Mar. 31 2026 
-3.55
-3.20
Beat
Dec. 31 2025 
-3.10
-3.50
Missed
Sep. 30 2025 
-3.44
-3.36
Beat